- Email: [email protected]
4693893 Vaccines for equine influenza
107
PATENT ABSTRACTS antibodies are used as diagnostic reagents in methods to determine the presence of anti-native DNA antibodies in serum from patients suspected of having systemic lupus erytbematosus. 4693888 CARIES-PREVENTIVE COMPOSITION Tsuneo Miyahara, Yoshihiro Harada, Katsuyuki Futakami, Yasukuni Nishida, Ryoko Konishi, Kanagawa, Japan assigned to Lion Corporation A caries-preventive composition comprises an antibody obtained by immunizing a mammal with at least one antigen selected from the group consisting of Streptococcus mutans, its cell-wall fraction, fibrous substance fraction, glucosyltransferase fraction and protein antigen fraction, and a synergist selected from the group consisting of fluorine compounds, chlorhexidine and its salts, lytic enzymes, bacteriocins, glucosyltransferase inhibitors, proteases and dextranases.
469~93 VACCINES FOR EQUINE INFLUENZA David Campbell assigned to Burroughs Wellcome It is known that the human influenza virus strain A/Puerto Rico/8/34 grows particularly well in eggs and that reassorted viruses having it as a parent may also grow well in eggs. It has now been found that certain reassortants of A/PR/8/34 and equine influenza viruses, namely those which comprise the RNA7 segment from A/PR/8/34, will grow in cell culture, even though the parent equine influenza vius will not. Thus the specification describes and claims: reassorted viruses comprising genes for surface antigens of equine influenza viruses and the RNA7 segment from A/PR/8/34; methods of obtaining such viruses by reassortment; methods of propagating such reassorted viruses in cell culture, especially Vero cells; vaccines against equine influenza comprising such reassorted viruses; and methods of vaccinating equines against influenza.
4693966 4693891 VACCINE
FOR PSEUDOMONAS AERUGINOSA
Michael Collins, Grace C Tsay, Richard L Seng assigned to Miles Laboratories Inc There is disclosed an immunizing composition comprising a non-toxic polysaccharide isolated from gram-negative bacteria, especially from Pseudomonas aeruginosa, covalently coupled to a non-toxic protein from the gram-positive bacterium Micrococcus luteus by means of a 4£14 12 carbon moiety. To prepare the above immunizing agent, the lipid A portion of lipopolysaccharide from a gram-negative bacterium is separated to give a non-toxic polysaccharide. Reactive aldehyde groups are generated on the non-toxic polysaccharide by selective oxidation. The non-toxic polysaccharide is then covalently coupled to a nontoxic protein isolated from said gram-positive bacterium, + I Micrococcus luteus, + L by means of a polyfunctional compound having 4 + 14 12 carbon atoms and having at least two functional groups which are reactive to the aldehyde groups on the non-toxic polysaccharide and to the carboxylic groups on the non-toxic protein.
HUMAN MONOCLONAL ANTIBODIES FROM LYMPHOCYTES OF PATIENTS WITH MALIGNANT MELANOMA Alan Houghton, Hannah Brooks, Richard Cote, Herbert F Oettgen, Lloyd J Old assigned to Sloan-Kettering Institute for Cancer Research Human monoclonal antibodies which specifically bind to antigens found on cell surfaces of renal, lung, and breast cancer cells, intracellular cytoskeletal antigens, nuclear antigens, and cytoplasmic reticular antigens are disclosed. The antibodies are the product of hybridoma cell lines, where the immortal cell line may be, e.g., a human cell line, or a murine cell line.
4693975 HUMAN HYBRIDROMA FUSION PARTNER FOR PRODUCTION OF HUMAN MONOCLONAL ANTIBODIES Danuta Kozbor, Carlo M Croce assigned to The Wistar Institute
PATENT ABSTRACTS antibodies are used as diagnostic reagents in methods to determine the presence of anti-native DNA antibodies in serum from patients suspected of having systemic lupus erytbematosus. 4693888 CARIES-PREVENTIVE COMPOSITION Tsuneo Miyahara, Yoshihiro Harada, Katsuyuki Futakami, Yasukuni Nishida, Ryoko Konishi, Kanagawa, Japan assigned to Lion Corporation A caries-preventive composition comprises an antibody obtained by immunizing a mammal with at least one antigen selected from the group consisting of Streptococcus mutans, its cell-wall fraction, fibrous substance fraction, glucosyltransferase fraction and protein antigen fraction, and a synergist selected from the group consisting of fluorine compounds, chlorhexidine and its salts, lytic enzymes, bacteriocins, glucosyltransferase inhibitors, proteases and dextranases.
469~93 VACCINES FOR EQUINE INFLUENZA David Campbell assigned to Burroughs Wellcome It is known that the human influenza virus strain A/Puerto Rico/8/34 grows particularly well in eggs and that reassorted viruses having it as a parent may also grow well in eggs. It has now been found that certain reassortants of A/PR/8/34 and equine influenza viruses, namely those which comprise the RNA7 segment from A/PR/8/34, will grow in cell culture, even though the parent equine influenza vius will not. Thus the specification describes and claims: reassorted viruses comprising genes for surface antigens of equine influenza viruses and the RNA7 segment from A/PR/8/34; methods of obtaining such viruses by reassortment; methods of propagating such reassorted viruses in cell culture, especially Vero cells; vaccines against equine influenza comprising such reassorted viruses; and methods of vaccinating equines against influenza.
4693966 4693891 VACCINE
FOR PSEUDOMONAS AERUGINOSA
Michael Collins, Grace C Tsay, Richard L Seng assigned to Miles Laboratories Inc There is disclosed an immunizing composition comprising a non-toxic polysaccharide isolated from gram-negative bacteria, especially from Pseudomonas aeruginosa, covalently coupled to a non-toxic protein from the gram-positive bacterium Micrococcus luteus by means of a 4£14 12 carbon moiety. To prepare the above immunizing agent, the lipid A portion of lipopolysaccharide from a gram-negative bacterium is separated to give a non-toxic polysaccharide. Reactive aldehyde groups are generated on the non-toxic polysaccharide by selective oxidation. The non-toxic polysaccharide is then covalently coupled to a nontoxic protein isolated from said gram-positive bacterium, + I Micrococcus luteus, + L by means of a polyfunctional compound having 4 + 14 12 carbon atoms and having at least two functional groups which are reactive to the aldehyde groups on the non-toxic polysaccharide and to the carboxylic groups on the non-toxic protein.
HUMAN MONOCLONAL ANTIBODIES FROM LYMPHOCYTES OF PATIENTS WITH MALIGNANT MELANOMA Alan Houghton, Hannah Brooks, Richard Cote, Herbert F Oettgen, Lloyd J Old assigned to Sloan-Kettering Institute for Cancer Research Human monoclonal antibodies which specifically bind to antigens found on cell surfaces of renal, lung, and breast cancer cells, intracellular cytoskeletal antigens, nuclear antigens, and cytoplasmic reticular antigens are disclosed. The antibodies are the product of hybridoma cell lines, where the immortal cell line may be, e.g., a human cell line, or a murine cell line.
4693975 HUMAN HYBRIDROMA FUSION PARTNER FOR PRODUCTION OF HUMAN MONOCLONAL ANTIBODIES Danuta Kozbor, Carlo M Croce assigned to The Wistar Institute